Similarly, Tanemura et al. reported low methylation frequency of RASSF1A in early stage melanoma but approximately 50% in stage III and IV melanoma samples [34], suggesting that RASSF1A methylation may potentially be an indicator of tumor progression. Here, RASSF1 is linked to melanoma.